Waldron Private Wealth LLC Increases Position in AstraZeneca PLC (NASDAQ:AZN)

Waldron Private Wealth LLC lifted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.9% in the third quarter, HoldingsChannel.com reports. The fund owned 3,838 shares of the company’s stock after acquiring an additional 314 shares during the period. Waldron Private Wealth LLC’s holdings in AstraZeneca were worth $299,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of AZN. McClarren Financial Advisors Inc. raised its position in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new position in AstraZeneca in the second quarter valued at approximately $26,000. Pathway Financial Advisers LLC purchased a new position in AstraZeneca in the first quarter valued at approximately $29,000. Hobbs Group Advisors LLC bought a new position in AstraZeneca during the second quarter valued at $35,000. Finally, Versant Capital Management Inc increased its position in AstraZeneca by 1,614.8% in the second quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock worth $36,000 after buying an additional 436 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, TD Cowen upped their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Stock Down 0.5 %

AZN opened at $76.95 on Thursday. The business’s fifty day simple moving average is $80.91 and its 200 day simple moving average is $78.42. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The stock has a market cap of $238.58 billion, a PE ratio of 37.72, a P/E/G ratio of 1.45 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.99 EPS for the quarter, beating the consensus estimate of $0.98 by $0.01. The firm had revenue of $12.45 billion for the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The company’s revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.08 EPS. As a group, research analysts expect that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.